RepliCel Life Sciences Inc.

Regenerative medicine company using autologous cells for healing tendinosis, skin aging and pattern baldness. TSX.V: $RP.V & OTCQB: $REPCF

[RepliCel Life Sciences Inc. @RepliCel]

RepliCel signs Letter of Intention (Asset Purchase)
https://t.co/8pfw0FR2mI

[RepliCel Life Sciences Inc. @RepliCel]

RepliCel Shareholders are invited to attend the AGM located at Clark Wilson LLP 900 – 885 West Georgia Street Vancouver, BC V6C 3H1 on September 22 at 2 PM Pacific. The AGM Zoom Link and Materials are posted on the RepliCel website located at https://t.co/3H3TbKbUM7

[RepliCel Life Sciences Inc. @RepliCel]

@Takeagander02 No worries, we will post the Zoom access link on the website on September 22 before the meeting at 2 p.m. PST. We will place it on the main page for your convenience.

[RepliCel Life Sciences Inc. @RepliCel]

Shareholders are invited to the RepliCel AGM scheduled for September 22 at 2 p.m. PST. We hope you can join in person at Clark Wilson LLP located at
900 – 885 West Georgia Street
Vancouver, BC V6C 3H1 or see website before meeting for online access.

[RepliCel Life Sciences Inc. @RepliCel]

In response to investor inquiries, RepliCel notes that the arbitration proceedings with Shiseido are ongoing. RepliCel respects the confidentiality rules of the ICDR and will provide material updates as they become available. We thank investors for their ongoing interest!

[RepliCel Life Sciences Inc. @RepliCel]

For more info visit the EHRS website here: https://t.co/eHaQnYERbF

[RepliCel Life Sciences Inc. @RepliCel]

CEO, Andrew Schutte and Chief Science Officer, Kevin McElwee attended the European Hair Research Society Biannual Conference in Sheffield, UK! Great connections and progress towards developing RCH-01 for Androgenetic Alopecia. We received a lot of interest in our functional commercial grade Dermaprecise injector. Thank you to the EHRS organizers for a fantastic event, many of whom we are collaborating with.

@researchhair @ehrs2023 #curebalding

[RepliCel Life Sciences Inc. @RepliCel]

RepliCel notes that the proceedings are ongoing and will further elaborate as circumstances allow. RepliCel is committed to commercializing RCH-01! RepliCel aims to have a fully calibrated commercial grade device in the coming months. We look forward to updating the market as material events unfold. #hairloss #innovation #progress

[RepliCel Life Sciences Inc. @RepliCel]

Thank you for attending our AGM! The two big takeaways that our CEO, Andrew Schutte, expressed are: 1) Obtaining a 510k approval for DermaPrecise this year 2) Concluding our ongoing arbitration proceedings, the hearing begins May 29th.

[Kevin McElwee @ResearchHair]

I’m en route to Canada 🇨🇦 today for @RepliCel AGM and meetings with scientists and business peeps. Of course I am flying by #hairplane ! 🌎🛩️🍁🔬🧫😁

[Mohsen Akbari @LiME_Akbari]

Wrapping up a productive day with ⁦@RepliCel⁩ and ⁦@ResearchHair⁩. Lots of science and planning for future collaborations.

[RepliCel Life Sciences Inc. @RepliCel]

RepliCel’s AGM is scheduled for February 28,2023 at 2 pm PST. It will be held in person at our legal office at Clark Wilson 900-855 West Georgia St. Vancouver BC, & virtually via Zoom. Our President & CEO Andrew Schutte will present alongside the Directors. Hope to see you there!

[RepliCel Life Sciences Inc. @RepliCel]

We are back from our trip to Japan. 🇯🇵 RepliCel is planning another visit to Japan in a few weeks. We are making progress and we won’t stop.

[RepliCel Life Sciences Inc. @RepliCel]

We just arrived in Japan! We are meeting with multiple potential investors and partners for all of our products: RCH-01 for regrowing hair, RCS-01 for rejuvenating skin, RCT-01 for repairing tendons,& DermaPrecise for precision injections. CEO Andrew Schutte is busy. Stay tuned.

[RepliCel Life Sciences Inc. @RepliCel]

RepliCel Provides Corporate Update
https://t.co/Wb9GMFe0Sd

[RepliCel Life Sciences Inc. @RepliCel]

@takeagander01 @DermaPrecise 4-5 years is clearly an exaggeration. The partnership is not dead by any means but moving forward has been very slow in China since COVID hit. Regulatory clearance for clinical studies is still pending. Launch of @DermaPrecise in Hong Kong after FDA approval is now our next goal.

[RepliCel Life Sciences Inc. @RepliCel]

The @DermaPrecise Injection System Shown to Produce Consistently High Cell Viability for Cell Therapy Injections. Testing performed by Innovacell
shows cell data superior using the DermaPrecise injector vs manual injections.
https://t.co/NXXHSuwsmD
#celltherapy #dermtwitter

[ScienceInsider @ScienceInsider]

How many papers might the new White House public access policy apply to? OSTP estimates 195,000 to 263,000 articles fed funded in 2020. That is ~7% to 9% of the 2.9 million papers published worldwide in 2020. From: p12 of economic analysis to Congress. https://t.co/sgmwoW86av

[RepliCel Life Sciences Inc. @RepliCel]

Great news for science transparency and the democratization of research data!

[ScienceInsider @ScienceInsider]

BREAKING: White House issues new policy that will require, by 2026, all federally-funded research results to be freely available to public without delay, ending longstanding ability of journals to paywall results for up to 1 year. Coverage coming on @ScienceInsider.